Skip to main content

Table 2 Annualized change In BMD

From: Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists

Group Lumbar spine Femoral neck
Control 0.4% 0.2%
Treated with CE + MPA -2.9% -2.2%
Treated with CE + MT + MPA 0% 1.6%
  1. BMD was measured using quantitative digital radiography (Hologic Inc, Waltham, MA, USA). CE, conjugated estrogens; MPA, medroxyprogesterone acetate; MT, methyltestosterone. P= 0.001, P = 0.006.